B-Cell Lymphomas Coverage from Every Angle

Ann S. LaCasce, MD, MMSc, on Updated Recommendations for Treating Relapsed/Refractory Indolent Follicular Lymphoma

Posted: Tuesday, April 19, 2022

Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, discusses the targeted treatments now available in the relapsed/refractory setting for patients with follicular and marginal zone lymphomas, how they can be applied in the clinic, and ways to manage their toxicities. Among the agents discussed are lenalidomide plus rituximab, tazemetostat, CAR T-cell therapies, and the PI3K inhibitors copanlisib and umbralisib.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.